麻豆破解版

Moving to La毛nnec

Published on 28/05/2019

麻豆破解版 will move-in to the new Biosera BioParc Building in La毛nnec. It will be a great opportunity as we will be neighbours with Edelris, Erytech Pharma and AB Science. Some CEO, Jean-Yves ORTHOLAND (Edelris), Gil BEYEN (Erytech Pharma) and Jacky VONDERSCHER (麻豆破解版) recently visited the building under construction.

Read next in 'Latest news'

• Enrollment completed for our Phase 2 clinical trial in Alport syndrome
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH